Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
RPRX affiliates reported multiple Rule 144 sales of Common Stock. The excerpt lists numerous dispositions by two related holders, TPC RP EPA1 LLC and TPC RP 2021 LLC, across January–March 2026. Examples include sales of 1,875 and 32,916 shares by those entities, respectively.
Reporting persons filed Form 144 reporting proposed and completed sales of Common Stock of RPRX. The excerpt lists multiple transactions by related entities, including sales on 12/17/2025, 01/07/2026, and 03/18/2026, with individual trade sizes such as 79,346, 123,965, and 100,462 shares respectively. Examples shown include sales by GWL 2014 G LLC (79,346 shares on 12/17/2025) and George Lloyd IRA (136,980 shares on 03/04/2026). The filing records gross proceeds for each sale in U.S. dollars alongside the share counts.
RPRX submitted a Form 144 reporting a proposed sale of 100,462 shares of Common Stock acquired on 06/20/2020.
The filing lists the broker Goldman Sachs & Co. LLC and records multiple sales by affiliated entities over the prior three months, including transactions dated 01/07/2026, 01/21/2026, and 03/04/2026 with share amounts and gross proceeds documented in the filing.
Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported indirect open-market sales of a total of 34,791 Class A ordinary shares of Royalty Pharma plc on March 2, 2026. The sales were made by entities TPC RP 2021, LLC and TPC RP EPA1 LLC at weighted average prices around $46.67 and $47.01 per share, in multiple transactions within disclosed price ranges. All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025.
Repare Therapeutics related entities reported multiple sales of common stock under a Form 144. The excerpt lists transactions by GWL 2013 NG LLC and GWL 2014 G LLC on several dates in December 2025 through February 2026.
Examples shown include 123,965 shares sold on 01/21/2026 and 110,000 shares sold on 12/03/2025. The filing records dollar proceeds for each sale in the excerpt.
TPC RP EPA1 LLC and TPC RP 2021 LLC reported multiple sales of Common Stock. The excerpt lists discrete market sales on several dates in 12/2025–02/2026, including transactions such as 108,759 shares for $4,659,572.71 on 02/03/2026 and 69,665 shares for $2,938,636.90 on 02/02/2026.
The filings show repeated, scheduled dispositions by affiliated entities rather than a single block sale; cash‑flow recipients are the named selling entities. Transaction timing and per‑trade amounts are shown inline with each sale record.
TPC RP EPA1 LLC and TPC RP 2021 LLC reported multiple sales of Common Stock. The excerpt lists discrete market sales on several dates in 12/2025–02/2026, including transactions such as 108,759 shares for $4,659,572.71 on 02/03/2026 and 69,665 shares for $2,938,636.90 on 02/02/2026.
The filings show repeated, scheduled dispositions by affiliated entities rather than a single block sale; cash‑flow recipients are the named selling entities. Transaction timing and per‑trade amounts are shown inline with each sale record.
Royalty Pharma plc insider reporting shows entities associated with EVP & CFO Terrance P. Coyne selling Class A Ordinary Shares of the company. On the reported date, TPC RP 2021, LLC and TPC RP EPA1 LLC together sold 34,791 shares in open-market transactions at a weighted average price of $45.3165 per share.
The filing notes these transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on August 8, 2025, which automates sales based on preset instructions. A footnote explains the reported sale price is an average, with individual trades executed between $44.97 and $45.60 per share.
RPRX affiliates submitted notices of proposed sales of Common Stock under Rule 144, listing multiple planned transactions across late 2025 and early 2026. Examples include sales by TPC RP EPA1 LLC and TPC RP 2021 LLC, such as $1,268,311.44 for 01/02/2026 and $4,659,572.71 for 02/03/2026 respectively.
Royalty Pharma plc’s Class A shareholder updates 13D stake. R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini report they may be deemed to beneficially own 24,223,082 Class A shares, representing 5.7% of Royalty Pharma’s outstanding Class A shares as of February 19, 2026.
The filing details holdings through sub-funds MGG Strategic and GG Strategic and extensive beneficial ownership disclaimers by the boards, trust beneficiaries, trustee and protector. It also notes prior sales and facility agreements that reduced pledged collateral shares and adjusted committed and uncommitted credit facility amounts.
Capital International Investors, a division of Capital Research and Management Company and affiliated investment management entities, reports beneficial ownership of 32,745,526 shares of Royalty Pharma PLC common stock, representing 7.7% of the 427,247,489 shares believed outstanding as of the event date.
The firm has sole voting power over 32,581,425 shares and sole dispositive power over 32,745,526 shares, with no shared voting or dispositive power. The securities are certified as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Royalty Pharma.